Literature DB >> 20623205

Preoperative diagnosis of nonfunctioning pancreatic neuroendocrine tumors.

Ji Li1, Guopei Luo, Deliang Fu, Chen Jin, Sijie Hao, Feng Yang, Xiaoyi Wang, Lie Yao, Quanxing Ni.   

Abstract

The aim of this study is to summarize the experience of preoperative diagnosis for nonfunctioning pancreatic neuroendocrine tumors (NFPNETs). The medical records of patients with NFPNETs were identified from 2001 to 2009 in a single center. They were all reviewed and analyzed for their demographics, clinical presentation, preoperative laboratory evaluation and radiographic characterization. Twenty-six patients (11 men and 15 women) in the past 8 years were diagnosed with NFPNETs. Almost all patients had the normal level of exocrine tumor markers. Although it was not difficult to find tumors by traditional imaging modalities including CT and MRI, the misdiagnosis rate was as high as 81.2%. Perfusion CT was helpful to predict the biological behavior of tumors and even identified NFPNETs as benign or malignant. The preoperative diagnosis for NFPNETs can be confirmed by one or the combination of CgA, perfusion CT, FNA-EUS, PET and octreoscans. NFPNETs should be aroused suspicion of normal exocrine tumor markers and relative specific imaging appearance, which can be proved by one or the combination of CgA, perfusion CT, FNA-EUS, PET and octreoscans.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20623205     DOI: 10.1007/s12032-010-9611-3

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  22 in total

1.  Neuroendocrine tumours of the pancreas.

Authors:  B Eriksson; K Oberg
Journal:  Br J Surg       Date:  2000-02       Impact factor: 6.939

Review 2.  Perfusion CT for the assessment of tumour vascularity: which protocol?

Authors:  K A Miles
Journal:  Br J Radiol       Date:  2003       Impact factor: 3.039

3.  Limited tumor involvement found at multiple endocrine neoplasia type I pancreatic exploration: can it be predicted by preoperative tumor localization?

Authors:  B Skogseid; K Oberg; G Akerström; B Eriksson; J E Westlin; E T Janson; H Eklöf; A Elvin; C Juhlin; J Rastad
Journal:  World J Surg       Date:  1998-07       Impact factor: 3.352

4.  Nonfunctioning malignant neuroendocrine tumors of the pancreas.

Authors:  F E Eckhauser; P S Cheung; A I Vinik; W E Strodel; R V Lloyd; N W Thompson
Journal:  Surgery       Date:  1986-12       Impact factor: 3.982

5.  Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs.

Authors:  M L Fjällskog; A Sundin; J E Westlin; K Oberg; E T Janson; B Eriksson
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

6.  Aggressive surgery for metastatic liver neuroendocrine tumors.

Authors:  Jeffrey A Norton; Robert S Warren; Mary G Kelly; Marlene B Zuraek; Robert T Jensen
Journal:  Surgery       Date:  2003-12       Impact factor: 3.982

7.  Usefulness of EUS-guided fine needle aspiration (EUS-FNA) in the diagnosis of functioning neuroendocrine tumors.

Authors:  Angels Ginès; Enrique Vazquez-Sequeiros; María Teresa Soria; Jonathan E Clain; Maurits J Wiersema
Journal:  Gastrointest Endosc       Date:  2002-08       Impact factor: 9.427

8.  Nonfunctioning islet cell tumors.

Authors:  R B Kent; J A van Heerden; L H Weiland
Journal:  Ann Surg       Date:  1981-02       Impact factor: 12.969

9.  Surgical management of malignant islet cell tumors.

Authors:  C S Grant
Journal:  World J Surg       Date:  1993 Jul-Aug       Impact factor: 3.352

10.  Nonfunctioning neuroendocrine pancreatic tumors: our experience and management.

Authors:  Naohiro Nomura; Tsutomu Fujii; Naohito Kanazumi; Shin Takeda; Shuji Nomoto; Hideki Kasuya; Hiroyuki Sugimoto; Suguru Yamada; Akimasa Nakao
Journal:  J Hepatobiliary Pancreat Surg       Date:  2009-04-14
View more
  4 in total

1.  Carbohydrate antigen 19-9 as a prognostic biomarker in pancreatic neuroendocrine tumors.

Authors:  Guopei Luo; Kaizhou Jin; He Cheng; Chen Liu; Meng Guo; Yu Lu; Chao Yang; Jinzhi Xu; Wenquan Wang; Heli Gao; Shirong Zhang; Jiang Long; Jin Xu; Quanxing Ni; Jie Chen; Xianjun Yu
Journal:  Oncol Lett       Date:  2017-09-26       Impact factor: 2.967

2.  Neutrophil-lymphocyte ratio predicts survival in pancreatic neuroendocrine tumors.

Authors:  Guopei Luo; Chen Liu; He Cheng; Kaizhou Jin; Meng Guo; Yu Lu; Jiang Long; Jin Xu; Quanxing Ni; Jie Chen; Xianjun Yu
Journal:  Oncol Lett       Date:  2017-02-13       Impact factor: 2.967

Review 3.  Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development.

Authors:  Rocio Garcia-Carbonero; Roberto Garcia-Figueiras; Alberto Carmona-Bayonas; Isabel Sevilla; Alex Teule; Maria Quindos; Enrique Grande; Jaume Capdevila; Javier Aller; Javier Arbizu; Paula Jimenez-Fonseca
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

4.  Serum Biomarker Status with a Distinctive Pattern in Prognosis of Gastroenteropancreatic Neuroendocrine Carcinoma.

Authors:  Jianwei Zhang; Yanshuo Cao; Panpan Zhang; Xiaotian Zhang; Jian Li; Jun Zhou; Xicheng Wang; Zhi Peng; Yu Sun; Jie Li; Lin Shen; Ming Lu
Journal:  Neuroendocrinology       Date:  2021-09-30       Impact factor: 5.135

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.